美聯儲古爾斯比：市場依然穩定；通脹遠高於目標，走勢不利。

The National Medical Products Administration, via its priority review channel, has granted conditional approval to Chengdu Bailiduote Biopharma Co., Ltd.'s injectable monoclonal antibody Lunkangyilongtuo (trade name Yizekang). Indication: adults with recurrent or metastatic nasopharyngeal carcinoma who progressed after at least two lines of systemic chemotherapy and prior PD‑1/PD‑L1 inhibitor therapy. The approval adds a new treatment option for this patient cohort.

港股芯片股部分反彈，芯智控股(02166.HK)漲超20%，國民技術(02701.HK)漲超17%，天數智芯(09903.HK)、中芯國際(00981.HK)漲近5%。